Cited by 24Congenital heart defects researchCardiac electrophysiology and arrhythmiasCongenital Heart Disease Studies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Multiple gene variations contributed to congenital heart disease via GATA family transcriptional regulation

Open access
Qian, Yanyan, Xiao, Deyong, Guo, Xiao, Chen, Hongbo, Hao, Lili, Ma, Xiaojing, Huang, Guoying, Ma, Duan, Wang, Huijun·2017·Journal of Translational Medicine

Abstract

BACKGROUND: Congenital heart disease (CHD) is a common birth defect, and most cases occur sporadically. Mutations in key genes that are responsible for cardiac development could contribute to CHD. To date, the genetic causes of CHD remain largely unknown. METHODS: In this study, twenty-nine candidate genes in CHD were sequenced in 106 patients with Tetralogy of Fallot (TOF) using target exome sequencing (TES). The co-immunoprecipitation (CO-IP) and luciferase reporter gene assays were performed in HEK293T cells, and wild-type and mutant mRNA of ZFPM2 were microinjected into zebrafish embryos. RESULTS: Rare variants in key cardiac transcriptional factors and JAG1 were identified in the patients. Four patients carried multiple gene variants. The novel E1148K variant was located at the eighth Zinc-finger domain of FOG2 protein. The CO-IP assays in the HEK293T cells revealed that the variant significantly damaged the interaction between ZFPM2/FOG2 and GATA4. The luciferase reporter gene assays revealed that the E1148K mutant ZFPM2 protein displayed a significantly greater inhibition of the transcriptional activation of GATA4 than the wild-type protein. The wild-type mRNA and the E1148K mutant mRNA of ZFPM2 were injected into zebrafish embryos. At 48 hpf, in the mutant mRNA injection group, the number of embryos with an abnormal cardiac chamber structure and a loss of left-right asymmetry was increased. By 72 hpf, the defects in the chamber and left-right asymmetry became obvious. CONCLUSIONS: We performed TES in sporadic TOF patients and identified rare variants in candidate genes in CHD. We first validated the E1148 K variant in ZFPM2, which is likely involved in the pathogenesis of CHD via GATA4. Moreover, our results suggest that TES could be a useful tool for discovering sequence variants in CHD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-017-1173-0

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Variants in the GATA family members. Blue boxes represent the transcription activation domains (TADs), and red boxes indicate the Zinc finger domains (ZFN). Sanger sequencing data are displayed, and the variants are shown in the red frames. Alignment of amino acid residues adjacent to the variants shows a conservation among different species, including human, mouse, dog and zebrafish. a Human GATA4 protein domain with the variants identified in the TOF patients. The GATA4 protein is composed of four functional domains. V380 M is located in the second TAD, and P407Q is located near the second TAD. Sanger sequencing data are displayed, and the variants are shown in the red frames. Amino acid in 407 is conserved in human, mouse and dog but not in zebrafish. b Human GATA5 protein domain with the variants identified in the TOF patients. GATA5 protein also has four functional domains, and the two novel variants are not located in the functional domain. Sanger sequencing data are displayed, and the variants are shown in the red frames. c Human GATA6 protein domain with the variants identified in the TOF patients. The GATA6 protein has five functional domains, including two TADs, two ZNFs and one nuclear location signal (NLS), which is presented by the yellow box. The variants D111 N and H324Q are localized at the TAD1 and TAD2, respectively. The amino acid in 111 is highly conserved in human, mouse, dog and zebrafish
Fig. 1 Variants in the GATA family members. Blue boxes represent the transcription activation domains (TADs), and red boxes indicate the Zinc finger domains (ZFN). Sanger sequencing data are displayed, and the variants are shown in the red frames. Alignment of amino acid residues adjacent to the variants shows a conservation among different species, including human, mouse, dog and zebrafish. a Human GATA4 protein domain with the variants identified in the TOF patients. The GATA4 protein is composed of four functional domains. V380 M is located in the second TAD, and P407Q is located near the second TAD. Sanger sequencing data are displayed, and the variants are shown in the red frames. Amino acid in 407 is conserved in human, mouse and dog but not in zebrafish. b Human GATA5 protein domain with the variants identified in the TOF patients. GATA5 protein also has four functional domains, and the two novel variants are not located in the functional domain. Sanger sequencing data are displayed, and the variants are shown in the red frames. c Human GATA6 protein domain with the variants identified in the TOF patients. The GATA6 protein has five functional domains, including two TADs, two ZNFs and one nuclear location signal (NLS), which is presented by the yellow box. The variants D111 N and H324Q are localized at the TAD1 and TAD2, respectively. The amino acid in 111 is highly conserved in human, mouse, dog and zebrafishCC BY · PubMed Central
Fig. 2 The variant of ZFPM2 attenuated the transcriptional activation of GATA4 and contributed to the cardiac abnormalities in zebrafish. a Diagram of the human ZFPM2/FOG2 protein domain with the location of its variants identified. The eight zinc-finger motifs (ZNF) are represented by yellow boxes. The nuclear localization signal (NLS) is indicated by a green box. The putative CtBP-binding site (CBS) is represented by a pink box. The N-terminal transcriptional repression domain (TRD) is indicated by a blue box. E1148 K found in B430 is located at the eighth Zinc-finger domain, and E1005G found in B548 is located in the seventh and eighth domains. Sanger sequencing shows the variant in the red frame. Both are conserved in human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red box. b Co-immunoprecipitation assays in HEK293T cells revealed that the E1148 K variant significantly damaged the interaction between ZFPM2 and GATA4 on the western blot. The semi-quantitative analysis of the western blot results shows that the E1148 K mutant ZFPM2 protein significantly disrupted the interaction with GATA4 compared to the wild-type ZFPM2 protein. The experiment was repeated three times. (p < 0.05 *, p < 0.01 **) c Luciferase reported gene assays were performed. The result revealed that the wild-type ZFPM2 protein could inhibit the transcriptional activation of GATA4 on the promoter of ANF. Furthermore, E1148 K inhibited the transcriptional activation of the GATA4 on the ANF promoter significantly more than the WT. Experiments were performed in triplicate, and the mean and standard deviations are shown. (*p < 0.05 and **p < 0.01). d Overexpression of the mutant ZFPM2 protein (E1148 K) contributes to the abnormal cardiac morphogenesis in the zebrafish embryos. In the control and wild-type human ZFPM2 mRNA injection groups, the embryos show normal cardiac left–right asymmetry at 48 and 72 hpf. The normal cardiac left–right asymmetry is “left (L)”: the ventricle is on the left side of the midline, and the atrium is on the right side. However, in the mutant mRNA injection group, the embryos showed the “right (R)” or “straight (S)” abnormal left–right asymmetry. e In each group, the cardiac morphogenesis of fifty embryos (n = 50) was analyzed. The number of embryos with cardiac defects, including size, left–right asymmetry, looping and pericardialites, was counted. The proportion of embryos with cardiac defects in the mutant human ZFPM2 protein (E1148 K) injection group is significantly higher than that in the other two groups. Three independent experiments were performed. (*p < 0.05 and **p < 0.01). f The nppa (zebrafish ANF gene) mRNA level in the embryos that received the E1148 K mutant human ZFPM2 mRNA injection is lower than that in the wild-type human ZFPM2 mRNA injection group. The mean and standard deviations are shown. Experiments were performed in triplicate. (*p < 0.05 and **p < 0.01)
Fig. 2 The variant of ZFPM2 attenuated the transcriptional activation of GATA4 and contributed to the cardiac abnormalities in zebrafish. a Diagram of the human ZFPM2/FOG2 protein domain with the location of its variants identified. The eight zinc-finger motifs (ZNF) are represented by yellow boxes. The nuclear localization signal (NLS) is indicated by a green box. The putative CtBP-binding site (CBS) is represented by a pink box. The N-terminal transcriptional repression domain (TRD) is indicated by a blue box. E1148 K found in B430 is located at the eighth Zinc-finger domain, and E1005G found in B548 is located in the seventh and eighth domains. Sanger sequencing shows the variant in the red frame. Both are conserved in human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red box. b Co-immunoprecipitation assays in HEK293T cells revealed that the E1148 K variant significantly damaged the interaction between ZFPM2 and GATA4 on the western blot. The semi-quantitative analysis of the western blot results shows that the E1148 K mutant ZFPM2 protein significantly disrupted the interaction with GATA4 compared to the wild-type ZFPM2 protein. The experiment was repeated three times. (p < 0.05 *, p < 0.01 **) c Luciferase reported gene assays were performed. The result revealed that the wild-type ZFPM2 protein could inhibit the transcriptional activation of GATA4 on the promoter of ANF. Furthermore, E1148 K inhibited the transcriptional activation of the GATA4 on the ANF promoter significantly more than the WT. Experiments were performed in triplicate, and the mean and standard deviations are shown. (*p < 0.05 and **p < 0.01). d Overexpression of the mutant ZFPM2 protein (E1148 K) contributes to the abnormal cardiac morphogenesis in the zebrafish embryos. In the control and wild-type human ZFPM2 mRNA injection groups, the embryos show normal cardiac left–right asymmetry at 48 and 72 hpf. The normal cardiac left–right asymmetry is “left (L)”: the ventricle is on the left side of the midline, and the atrium is on the right side. However, in the mutant mRNA injection group, the embryos showed the “right (R)” or “straight (S)” abnormal left–right asymmetry. e In each group, the cardiac morphogenesis of fifty embryos (n = 50) was analyzed. The number of embryos with cardiac defects, including size, left–right asymmetry, looping and pericardialites, was counted. The proportion of embryos with cardiac defects in the mutant human ZFPM2 protein (E1148 K) injection group is significantly higher than that in the other two groups. Three independent experiments were performed. (*p < 0.05 and **p < 0.01). f The nppa (zebrafish ANF gene) mRNA level in the embryos that received the E1148 K mutant human ZFPM2 mRNA injection is lower than that in the wild-type human ZFPM2 mRNA injection group. The mean and standard deviations are shown. Experiments were performed in triplicate. (*p < 0.05 and **p < 0.01)CC BY · PubMed Central
Fig. 3 Rare variants of JAG1 identified in patients. Human JAG1 protein structures with the location of the variants identified are shown above the diagram. The amino acid positions of the putative JAG1 functional domains are shown below the protein diagram. Blue box represents the signal peptide, and the green box indicates the DSL domain. In addition, the dark blue boxes show the EGF repeat domains, and the orange box represents the transmembrane domain. Four variants (p.P269R, p.N504S, p. M969T, p. H1013L) of JAG1 were identified and were conservative in different species, including human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red frame. All variants were confirmed by Sanger sequencing and are shown in the red frames. The variant p. N504S is located on the EGF repeats domain, and the other three variants are not in the functional domain
Fig. 3 Rare variants of JAG1 identified in patients. Human JAG1 protein structures with the location of the variants identified are shown above the diagram. The amino acid positions of the putative JAG1 functional domains are shown below the protein diagram. Blue box represents the signal peptide, and the green box indicates the DSL domain. In addition, the dark blue boxes show the EGF repeat domains, and the orange box represents the transmembrane domain. Four variants (p.P269R, p.N504S, p. M969T, p. H1013L) of JAG1 were identified and were conservative in different species, including human, mouse, dog and zebrafish. The amino acid residue altered by the mutation is shown in the red frame. All variants were confirmed by Sanger sequencing and are shown in the red frames. The variant p. N504S is located on the EGF repeats domain, and the other three variants are not in the functional domainCC BY · PubMed Central
Fig. 4 Two possible genetic etiologies of CHD. a Monogenic mutations in a key cardiac regulator may be the cause of CHD. A pathogenic E1148 K variant of ZFPM2 in patient B430 decreased the binding of ZFPM2 and GATA4 and attenuated the transcriptional activation of GATA4 on the promoter of ANF. b The majority of the variants in the GATA family member genes and JAG1 occurred sporadically in the patients. However, patients B294 and B393 carried two variants in two genes. B393 carried one variant in JAG1 and one variant in GATA6 variant, shown in a blue color, and B294 carried one variant in JAG1 and one variant in GATA5, shown in a green color. The results support the notion that rare, moderate-effect gene variants occur simultaneously in patients and may increase the susceptibility to cardiac malformations. The interaction between NOTCH signaling and the GATA family members is indispensable for cardiac development
Fig. 4 Two possible genetic etiologies of CHD. a Monogenic mutations in a key cardiac regulator may be the cause of CHD. A pathogenic E1148 K variant of ZFPM2 in patient B430 decreased the binding of ZFPM2 and GATA4 and attenuated the transcriptional activation of GATA4 on the promoter of ANF. b The majority of the variants in the GATA family member genes and JAG1 occurred sporadically in the patients. However, patients B294 and B393 carried two variants in two genes. B393 carried one variant in JAG1 and one variant in GATA6 variant, shown in a blue color, and B294 carried one variant in JAG1 and one variant in GATA5, shown in a green color. The results support the notion that rare, moderate-effect gene variants occur simultaneously in patients and may increase the susceptibility to cardiac malformations. The interaction between NOTCH signaling and the GATA family members is indispensable for cardiac developmentCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Pierpont ME, Basson CT, Benson DW Jr, Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, Srivastava D, Webb CL. American Heart Association Congenital Cardiac Defects Committee CoCDitY: genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007;115:3015–38. · DOI
  2. Zhao QM, Ma XJ, Jia B, Huang GY. Prevalence of congenital heart disease at live birth: an accurate assessment by echocardiographic screening. Acta Paediatr. 2013;102:397–402. · DOI
  3. Grunert M, Dorn C, Schueler M, Dunkel I, Schlesinger J, Mebus S, Alexi-Meskishvili V, Perrot A, Wassilew K, Timmermann B, et al. Rare and private variations in neural crest, apoptosis and sarcomere genes define the polygenic background of isolated Tetralogy of Fallot. Hum Mol Genet. 2014;23:3115–28. · DOI
  4. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol. 2012;100:253–77. · DOI
  5. Ruiz-Villalba A, Hoppler S, van den Hoff MJ. Wnt signaling in the heart fields: variations on a common theme. Dev Dyn. 2016;245:294–306. · DOI
  6. Luxan G, D’Amato G, MacGrogan D, de la Pompa JL. Endocardial notch signaling in cardiac development and disease. Circ Res. 2016;118:e1–18. · DOI
  7. Bevilacqua A, Willis MS, Bultman SJ. SWI/SNF chromatin-remodeling complexes in cardiovascular development and disease. Cardiovasc Pathol. 2014;23:85–91. · DOI
  8. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K, et al. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003;424:443–7. · DOI
  9. Wang J, Lu Y, Chen H, Yin M, Yu T, Fu Q. Investigation of somatic NKX2-5, GATA4 and HAND1 mutations in patients with Tetralogy of Fallot. Pathology. 2011;43:322–6. · DOI
  10. Bauer RC, Laney AO, Smith R, Gerfen J, Morrissette JJ, Woyciechowski S, Garbarini J, Loomes KM, Krantz ID, Urban Z, et al. Jagged1 (JAG1) mutations in patients with Tetralogy of Fallot or pulmonic stenosis. Hum Mutat. 2010;31:594–601. · DOI
  11. Srivastava D. Genetic regulation of cardiogenesis and congenital heart disease. Annu Rev Pathol. 2006;1:199–213. · DOI
  12. Su W, Zhu P, Wang R, Wu Q, Wang M, Zhang X, Mei L, Tang J, Kumar M, Wang X, et al. Congenital heart diseases and their association with the variant distribution features on susceptibility genes. Clin Genet. 2017;91:349–54. · DOI
  13. Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, Kudo H, Daigo K, et al. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol. 2007;27:4248–60. · DOI
  14. Gallagher JM, Yamak A, Kirilenko P, Black S, Bochtler M, Lefebvre C, Nemer M, Latinkic BV. Carboxy terminus of GATA4 transcription factor is required for its cardiogenic activity and interaction with CDK4. Mech Dev. 2014;134:31–41. · DOI
  15. Prendiville T, Jay PY, Pu WT. Insights into the genetic structure of congenital heart disease from human and murine studies on monogenic disorders. Cold Spring Harb Perspect Med. 2014;4:a013946. · DOI
  16. Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K, Takahashi T, Matsuoka R, Yamagishi H. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc Natl Acad Sci USA. 2009;106:13933–8. · DOI
  17. Jiang JQ, Li RG, Wang J, Liu XY, Xu YJ, Fang WY, Chen XZ, Zhang W, Wang XZ, Yang YQ. Prevalence and spectrum of GATA5 mutations associated with congenital heart disease. Int J Cardiol. 2013;165:570–3. · DOI
  18. Granados-Riveron JT, Pope M, Bu’lock FA, Thornborough C, Eason J, Setchfield K, Ketley A, Kirk EP, Fatkin D, Feneley MP, et al. Combined mutation screening of NKX2-5, GATA4, and TBX5 in congenital heart disease: multiple heterozygosity and novel mutations. Congenit Heart Dis. 2012;7:151–9. · DOI
  19. Garnatz AS, Gao Z, Broman M, Martens S, Earley JU, Svensson EC. FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte proliferation during heart development. Dev Biol. 2014;395:50–61. · DOI
  20. Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD, Orkin SH. Proper coronary vascular development and heart morphogenesis depend on interaction of GATA-4 with FOG cofactors. Genes Dev. 2001;15:839–44. · DOI
  21. Pizzuti A, Sarkozy A, Newton AL, Conti E, Flex E, Digilio MC, Amati F, Gianni D, Tandoi C, Marino B, et al. Mutations of ZFPM2/FOG2 gene in sporadic cases of Tetralogy of Fallot. Hum Mutat. 2003;22:372–7. · DOI
  22. De Luca A, Sarkozy A, Ferese R, Consoli F, Lepri F, Dentici ML, Vergara P, De Zorzi A, Versacci P, Digilio MC, et al. New mutations in ZFPM2/FOG2 gene in Tetralogy of Fallot and double outlet right ventricle. Clin Genet. 2011;80:184–90. · DOI
  23. Tan ZP, Huang C, Xu ZB, Yang JF, Yang YF. Novel ZFPM2/FOG2 variants in patients with double outlet right ventricle. Clin Genet. 2012;82:466–71. · DOI
  24. Luna-Zurita L, Prados B, Grego-Bessa J, Luxan G, del Monte G, Benguria A, Adams RH, Perez-Pomares JM, de la Pompa JL. Integration of a notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J Clin Invest. 2010;120:3493–507. · DOI
  25. Fischer A, Klattig J, Kneitz B, Diez H, Maier M, Holtmann B, Englert C, Gessler M. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol. 2005;25:8960–70. · DOI
  26. Fischer A, Klamt B, Schumacher N, Glaeser C, Hansmann I, Fenge H, Gessler M. Phenotypic variability in Hey2 −/− mice and absence of HEY2 mutations in patients with congenital heart defects or Alagille syndrome. Mamm Genome. 2004;15:711–6. · DOI
  27. Jones EA, Clement-Jones M, Wilson DI. JAGGED1 expression in human embryos: correlation with the Alagille syndrome phenotype. J Med Genet. 2000;37:658–62. · DOI
  28. High FA, Jain R, Stoller JZ, Antonucci NB, Lu MM, Loomes KM, Kaestner KH, Pear WS, Epstein JA. Murine Jagged1/Notch signaling in the second heart field orchestrates Fgf8 expression and tissue-tissue interactions during outflow tract development. J Clin Invest. 2009;119:1986–96.
  29. Hofmann JJ, Briot A, Enciso J, Zovein AC, Ren S, Zhang ZW, Radtke F, Simons M, Wang Y, Iruela-Arispe ML. Endothelial deletion of murine Jag1 leads to valve calcification and congenital heart defects associated with Alagille syndrome. Development. 2012;139:4449–60. · DOI
  30. Jia Y, Louw JJ, Breckpot J, Callewaert B, Barrea C, Sznajer Y, Gewillig M, Souche E, Dehaspe L, Vermeesch JR, et al. The diagnostic value of next generation sequencing in familial nonsyndromic congenital heart defects. Am J Med Genet A. 2015;167A:1822–9. · DOI
  31. Blue GM, Kirk EP, Giannoulatou E, Dunwoodie SL, Ho JW, Hilton DC, White SM, Sholler GF, Harvey RP, Winlaw DS. Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. J Am Coll Cardiol. 2014;64:2498–506. · DOI
  32. Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, McKean D, Wakimoto H, Gorham J, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015;350:1262–6. · DOI
  33. Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, Parmacek MS, Soudais C, Leiden JM. GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev. 1997;11:1048–60. · DOI
  34. Morrisey EE, Tang Z, Sigrist K, Lu MM, Jiang F, Ip HS, Parmacek MS. GATA6 regulates HNF4 and is required for differentiation of visceral endoderm in the mouse embryo. Genes Dev. 1998;12:3579–90. · DOI
  35. Laforest B, Andelfinger G, Nemer M. Loss of Gata5 in mice leads to bicuspid aortic valve. J Clin Invest. 2011;121:2876–87. · DOI · Paper page
  36. Zhang W, Li X, Shen A, Jiao W, Guan X, Li Z. GATA4 mutations in 486 Chinese patients with congenital heart disease. Eur J Med Genet. 2008;51:527–35. · DOI
  37. Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G, Orkin SH. FOG-2: a novel GATA-family cofactor related to multitype zinc-finger proteins friend of GATA-1 and U-shaped. Proc Natl Acad Sci USA. 1999;96:950–5. · DOI
  38. Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN. FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol. 1999;19:4495–502. · DOI
  39. Grepin C, Dagnino L, Robitaille L, Haberstroh L, Antakly T, Nemer M. A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol. 1994;14:3115–29. · DOI
  40. Shimizu K, Chiba S, Saito T, Kumano K, Hirai H. Physical interaction of Delta1, Jagged1, and Jagged2 with Notch1 and Notch3 receptors. Biochem Biophys Res Commun. 2000;276:385–9. · DOI
  41. Warthen DM, Moore EC, Kamath BM, Morrissette JJ, Sanchez-Lara PA, Piccoli DA, Krantz ID, Spinner NB. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate. Hum Mutat. 2006;27:436–43. · DOI
  42. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, Gendron-Maguire M, Rand EB, Weinmaster G, Gridley T. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet. 1999;8:723–30. · DOI
  43. McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development. 2002;129:1075–82. · DOI
  44. Xiang F, Sakata Y, Cui L, Youngblood JM, Nakagami H, Liao JK, Liao R, Chin MT. Transcription factor CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with GATA4. Am J Physiol Heart Circ Physiol. 2006;290:H1997–2006. · DOI
  45. Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the developing heart. Cardiovasc Res. 2011;91:212–22. · DOI
  46. Pang S, Liu Y, Zhao Z, Huang W, Chen D, Yan B. Novel and functional sequence variants within the TBX2 gene promoter in ventricular septal defects. Biochimie. 2013;95:1807–9. · DOI

Cited by

Sorted by citations

See all 24

Metadata

Authors
Qian, Y., Xiao, D., Guo, X., Chen, H., Hao, L., Ma, X., Huang, G., Ma, D., & Wang, H.
Affiliations
  • Shanghai Medical College of Fudan University (CN)
  • Fudan University (CN)
  • Children's Hospital of Fudan University (CN)
Corresponding author
  • Ma, Duan
  • Wang, Huijun
Venue
Journal of Translational Medicine
Published
2017-04-03
Volume
15
Issue
1
Pages
69-69
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2604158690
Cited by
24
References
1
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 4 · 2018: 5
FWCI
1.56
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81471483, 81570286)
  • National Key Research and Development Program (2016YFC1000500)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Congenital Heart Disease Studies
Keywords
congenital heart disease, tetralogy of Fallot, ZFPM2, FOG2, GATA4, GATA transcription factors, JAG1, rare variants, zinc finger, transcriptional regulation, heart development, left-right asymmetry
MeSH terms
Adolescent, Amino Acid Sequence, Animals, Base Sequence, Child, Child, Preschool, Female, Gene Expression Regulation, Heart Defects, Congenital, Humans, Infant, Infant, Newborn, Male, Tetralogy of Fallot, Transcription, Genetic, Genetic Variation, Zebrafish, Transcriptional Activation, GATA Transcription Factors, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review